The World Health Organization has published a new edition of its Model List of Essential Medicines, including groundbreaking treatments for hepatitis C and multi-drug resistant tuberculosis.
This will enable public health bodies globally to improve access to innovative medicines with clear clinical benefits. Margaret Chan, director general of the WHO, said: “When new effective medicines emerge to safely treat serious and widespread diseases, it is vital to ensure that everyone who needs them can obtain them. Placing them on the WHO Essential Medicines List is a first step in that direction.”
The list is updated every two years by an expert committee, which this year highlighted the urgent need to take action and promote equitable access to several new highly effective medicines, some currently too costly for even high-income countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze